Ralph Lauren beats forecasts and Bitcoin hits record highs, driven by strong earnings and regulatory optimism amid market volatility.
Market-Moving Event Alerts
Remember to move the mail to the Primary inbox if this mail is in other inboxes.
This week, 25% of alerts generated by StockNews.AI captured price movements exceeding 10%, marking a new all-time high.
*Data Captured Between 5/19 00:00am - 5/23 12:00 pm EDT.
*Penny stocks are excluded from the 10%+ price change analysis.
Top 3 AI Events you can’t miss for today, 5/23.
Benzinga
BullishShortTermRLEarnings
Ralph Lauren Analysts Boost Their Forecasts After Upbeat Q4 Results
- Ralph Lauren's Q4 sales rose 8%, exceeding expectations.
- Adjusted EPS of $2.27 beat the forecast of $2.00.
- Future revenue growth is projected in low-single digits for FY26.
- Analysts adjusted price targets, with Jefferies raising it to $328.
- Stock fell 1.4% post-earnings release despite positive results.
Barrons
bullishLongTermJPMCorporate Developments
Bitcoin Price Falls Back From Highs. Trump Tariff Threats Are Hurting Cryptos. - Barron's
- JPMorgan and Citigroup explore a joint stablecoin.
- Trump's tariff threats caused market volatility and crypto decline.
- New legislation on stablecoins may boost institutional demand.
- Market uncertainty typically drives investors to safe-haven assets.
- Crypto rally attributed to regulatory optimism and capital inflows.
Market Watch
BullishShortTermBTCUSDIndustry News
Why bitcoin has rallied to a $112,000 record high while stocks are wobbling - MarketWatch
- Bitcoin hit a record high, diverging from stocks.
- Resilience during market turbulence linked to regulatory optimism.
- Institutional investments in crypto are increasing.
- States consider establishing bitcoin reserves, enhancing legitimacy.
- New stablecoin legislation could promote wider adoption.
Here’re the top 5 most-surged stocks captured by our AI Event signal this week.
*Penny stocks are not included in the list.
GlobeNewsWire
BullishLongTerm 241.13%VIGLM&A
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
- Sanofi to acquire Vigil for $10.00 per share, closing in Q3 2025.
- Transaction strengthens development of VG-3927, a potential Alzheimer's treatment.
- Shareholders receive $8.00 cash plus $2.00 CVR upon VG-3927's commercial sale.
- Important merger leverages Sanofi's capabilities in neurology and immunology.
- Iluzanebart (VGL101) program will not be acquired, returning to Amgen.
GlobeNewsWire
BullishShortTerm 118.99%MRMEarnings
MEDIROM Healthcare Technologies Inc. Announces 22% Rise in Revenue and 20% Improvement in Earnings for 2024; Webcast to Discuss Financial Results to be held on May 21st, 2025 at 8:30 AM ET
- MRM's revenue increased by 22% to $52.74 million in 2024.
- Net income improved 20% to $878,000, surpassing last year's figures.
- Cost of revenues decreased, improving profitability metrics significantly.
- Plans for expanding digital health initiatives and user bases are underway.
- Recent financing activities generated approximately $5 million for growth.
PRNewsWire
VerybullishShortTerm 67.03%CFSBM&A
Hometown Financial Group, Inc. to Acquire CFSB Bancorp, Inc.
- CFSB to be acquired by Hometown Financial for $14.25 per share.
- The merger values CFSB at approximately $44 million.
- The transaction will consolidate assets totaling nearly $6.9 billion post-merger.
- CFSB branches to merge into North Shore Bank expanding its market.
- Hometown's merger aims to enhance customer service and product offerings.
GlobeNewsWire
BullishLongTerm 47.79%EYENM&A
Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results
- Eyenovia negotiating merger with Betaliq, exclusivity extended until June 7, 2025.
- Optejet user-filled device development on track for U.S. approval in September 2025.
- Company has reduced cash burn by 70%, improving financial stability.
- First quarter 2025 net loss decreased significantly to $3.5 million from $10.9 million.
- Management aims to maximize shareholder value through merger and new product opportunities.
GlobeNewsWire
BullishLongTerm 32.92%TILEarnings
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
- Instil Bio's '2510 trial in NSCLC starts mid-2026 in China.
- US Phase 1b/2 trial for '2510 to start by end of 2025.
- Initial safety and efficacy data for '2510 expected in late 2025.
- Current objective response rate for '2510 in NSCLC is 23%.
- Collaboration with ImmuneOnco shows promising clinical advancements for '2510.
GlobeNewsWire
BullishLongTerm 30.8%GPUSEarnings
Hyperscale Data Provides Business Update; Reports $25 Million in Q1 Revenue and Reaffirms $115–$125 Million Full-Year Revenue Guidance
- Hyperscale Data reports $25 million revenue for Q1 2025.
- Reaffirms 2025 revenue guidance of $115-$125 million.
- Strong performance noted in AI-driven Michigan data center.
- Growth expected from AI software subsidiary and Bitcoin mining activities.
- Company plans to spin off non-core Ault Capital Group by end of 2025.
Want to see customized event news?
Subscribe and Activate Event Alert Today!
Disclaimer: The content provided in this Email should be used for informational purposes only and in no way should be relied upon for financial advice.
Reply